Association of angiogenic factors with prognosis in esophageal cancer.

Abstract

BACKGROUND:

Despite multimodal therapy esophageal cancer often presents with poor prognosis. To improve outcome, tumor angiogenesis and anti-angiogenic therapeutic agents have recently gained importance. However, patient subgroups who benefit from anti-angiogenic therapy are not yet defined. In this retrospective exploratory study we investigated 9 angiogenic factors in patients' serum and tissue samples with regard to their association with clinicopathological parameters, prognosis and response in patients with locally advanced preoperatively treated esophageal cancer.

METHODS:

From 2007 to 2012 preoperative serum and corresponding tumor tissue (n = 54), only serum (n = 20) or only tumor tissue (n = 4) were collected from esophageal squamous cell carcinoma (SCC) (n = 34) and adenocarcinoma of the esophagogastric junction (AEG) (n = 44) staged cT3/4NanyM0/x after preoperative chemo(radio)therapy. Angiogenic cytokine levels in both tissue and serum were measured by multiplex immunoassay.

RESULTS:

Median survival in all patients was 28.49 months. No significant difference was found in survival between SCC and AEG (p = 0.90). 26 patients were histopathological responders. Histopathological response was associated with prognosis (p = 0.05). Angiogenic factors were associated with the following clinicopathological factors: tumor tissue expression of Angiopoietin-2 and Follistatin was higher in SCC compared to AEG (p = 0.022 and p = 0.001). High HGF and Follistatin expression in the tumor tissue was associated with poor prognosis in all patients (p = 0.037 and p = 0.036). No association with prognosis was found in the patients' serum. Neither patients' serum nor tumor tissue showed an association between angiogenic factors and response to neoadjuvant therapy.

CONCLUSION:

Two angiogenic factors (HGF and Follistatin) in posttherapeutic tumor tissue are associated with prognosis in esophageal cancer patients. Biological differences of AEG and SCC with respect to angiogenesis were evident by the different expression of 2 angiogenic factors. Results are promising and should be pursued prospectively, optimally sequentially pre- and posttherapeutically.

• Authors: Lena Dreikhausen, Susanne Blank, Leila Sisic, Ulrike Heger, Wilko Weichert, Dirk Jäger, Thomas Bruckner, Natalia Giese, Lars Grenacher, Christine Falk, Katja Ott, Thomas Schmidt
• Journal: BMC cancer (BMC Cancer) Vol. 15 Pg. 121 (Mar 13 2015) ISSN: 1471-2407 [Electronic] England
• PMID: 25885021 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• FST protein, human
• Follistatin
• HGF protein, human
• Hepatocyte Growth Factor

Topics

• Adenocarcinoma (diagnosis, metabolism)
• Adult
• Aged
• Aged, 80 and over
• Biomarkers, Tumor (biosynthesis)
• Carcinoma, Squamous Cell (diagnosis, metabolism)
• Esophageal Neoplasms (diagnosis, metabolism)
• Esophageal Squamous Cell Carcinoma
• Female
• Follistatin (biosynthesis)
• Follow-Up Studies
• Hepatocyte Growth Factor (biosynthesis)
• Humans
• Male
• Middle Aged
• Prognosis